Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: Evidence to date Review
| Authors: | Zavras, P. D.; Wang, Y.; Gandhi, A.; Lontos, K.; Delgoffe, G. M. |
| Review Title: | Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: Evidence to date |
| Abstract: | Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials. © 2019 Zavras et al. |
| Keywords: | lymphoma; dlbcl; diffuse large b cell lymphoma; tisagenlecleucel; car t; refractory dlbcl |
| Journal Title: | OncoTargets and Therapy |
| Volume: | 12 |
| ISSN: | 1178-6930 |
| Publisher: | Dove Medical Press Ltd |
| Date Published: | 2019-06-11 |
| Start Page: | 4543 |
| End Page: | 4554 |
| Language: | English |
| DOI: | 10.2147/ott.S177844 |
| PROVIDER: | scopus |
| PMCID: | PMC6572744 |
| PUBMED: | 31354288 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 August 2019 -- Source: Scopus |
